Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers.

Acute graft-versus-host disease (aGVHD) remains a life-threatening complication of hematopoietic stem cell transplantation (HSCT) therefore limiting its application. To optimize the management of aGVHD and reduce therapy-related toxicity, early specific markers are needed. The main objective of this study was to uncover diagnostic biomarkers by comparing plasma protein profiles of patients at the time of acute GVHD diagnosis with those of patients undergoing HSCT without aGVHD. Additional analysis of samples taken 15 days before aGVHD diagnosis was also performed to evaluate the potential of our newly discovered biomarkers for early diagnosis. To get complementary information from plasma samples, we used three different proteomic approaches, namely 2D-DIGE, SELDI-TOF-MS and 2D-LC-MS(E). We identified and confirmed by the means of independent techniques, the differential expression of several proteins indicating significantly increased inflammation response and disturbance in the coagulation cascade. The variation of these proteins was already observed 15 days before GVHD diagnosis, suggesting the potential early detection of the disease before symptoms appearance. Finally, logistic regression analysis determined a composite biomarker panel comprising fibrinogen, fragment of fibrinogen beta chain, SAA, prothrombin fragments, apolipoprotein A1 and hepcidin that optimally discriminated patients with and without GVHD. The area under the receiver operating characteristic curve distinguishing these 2 groups was 0.95.

[1]  M. Fillet,et al.  Development of a nano-liquid chromatography on chip tandem mass spectrometry method for high-sensitivity hepcidin quantitation. , 2011, Journal of chromatography. A.

[2]  L. Zhao,et al.  Evaluation of published single nucleotide polymorphisms associated with acute GVHD. , 2012, Blood.

[3]  C. Esmon.  The interactions between inflammation and coagulation , 2005, British journal of haematology.

[4]  Thomas M Braun,et al.  Plasma biomarkers in graft-versus-host disease: a new era? , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  Ruth Etzioni,et al.  Early detection: The case for early detection , 2003, Nature Reviews Cancer.

[6]  S. Yamasaki,et al.  Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  S. Urieli-Shoval,et al.  Human serum amyloid A genes are expressed in monocyte/macrophage cell lines. , 1994, The American journal of pathology.

[8]  William Arbuthnot Sir Lane,et al.  Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. , 1992, The Journal of biological chemistry.

[9]  N. Hyka,et al.  Articles on similar topics can be found in the following Blood collections , 2013 .

[10]  A. Tsatsakis,et al.  Lumican, a small leucine‐rich proteoglycan , 2008, IUBMB life.

[11]  R. Soiffer,et al.  The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[12]  Elizabeta Nemeth,et al.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. , 2003, Blood.

[13]  H. Shiku,et al.  Hemostatic Abnormalities and Changes Following Bone Marrow Transplantation , 2004, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[14]  David E. Misek,et al.  Intact-protein-based High-resolution Three-dimensional Quantitative Analysis System for Proteome Profiling of Biological Fluids* , 2005, Molecular & Cellular Proteomics.

[15]  H. Deeg,et al.  How I treat refractory acute GVHD. , 2007, Blood.

[16]  A. Whitehead,et al.  Serum amyloid A, the major vertebrate acute-phase reactant. , 1999, European journal of biochemistry.

[17]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Pihusch.  Bleeding complications after hematopoietic stem cell transplantation. , 2004, Seminars in hematology.

[19]  Jean-Paul Chapelle,et al.  Comparison of three methods for fractionation and enrichment of low molecular weight proteins for SELDI-TOF-MS differential analysis. , 2010, Talanta.

[20]  V. Thulasiraman,et al.  Reducing protein concentration range of biological samples using solid-phase ligand libraries. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  A. Sun,et al.  Alterations of hemostatic parameters in the early development of allogeneic hematopoietic stem cell transplantation-related complications , 2011, Annals of Hematology.

[22]  M. Hulett,et al.  Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. , 2011, Blood.

[23]  H. Shulman,et al.  Iron overload, hematopoietic cell transplantation, and graft-versus-host disease , 2009, Leukemia & lymphoma.

[24]  T. van der Poll,et al.  Activation of coagulation after administration of tumor necrosis factor to normal subjects. , 1990, The New England journal of medicine.

[25]  M. Mosesson.  Fibrinogen and fibrin structure and functions , 2005, Journal of thrombosis and haemostasis : JTH.

[26]  T. Miida,et al.  Characterization of serum amyloid A4 as a plasma apolipoprotein. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[27]  A. Whitehead,et al.  A constitutively expressed serum amyloid A protein gene (SAA4) is closely linked to, and shares structural similarities with, an acute-phase serum amyloid A protein gene (SAA2). , 1993, Genomics.

[28]  Thomas M Braun,et al.  A biomarker panel for acute graft-versus-host disease. , 2009, Blood.

[29]  H. Tsutsumi,et al.  CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. , 2008, Blood.

[30]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[31]  K. Sullivan.  Graft‐vs.‐Host Disease , 2007 .

[32]  W. Landman,et al.  Extrahepatic production of acute phase serum amyloid A. , 2005, Histology and histopathology.

[33]  F. D. de Beer,et al.  Human serum amyloid A (SAA) protein: a prominent acute‐phase reactant for clinical practice , 1996, European journal of clinical investigation.

[34]  E. Holler,et al.  Graft-versus-host disease , 2009, The Lancet.

[35]  C. McCulloch,et al.  Multifunctional roles of gelsolin in health and diseases , 2012, Medicinal research reviews.

[36]  M. Hulett,et al.  Histidine‐rich glycoprotein: A novel adaptor protein in plasma that modulates the immune, vascular and coagulation systems , 2005, Immunology and cell biology.

[37]  Thomas M Braun,et al.  Plasma biomarkers of lower gastrointestinal and liver acute GVHD. , 2012, Blood.

[38]  C. Salat,et al.  Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft‐versus‐host disease of the gut , 2002, British journal of haematology.

[39]  L. Joutsi-Korhonen,et al.  Early thrombin generation and impaired fibrinolysis after SCT associate with acute GVHD , 2010, Bone Marrow Transplantation.

[40]  B. Blazar,et al.  Acute graft-versus-host disease: from the bench to the bedside. , 2005, Blood.

[41]  S. Steinberg,et al.  Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Sipe,et al.  Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation. , 1978, The Journal of clinical investigation.

[43]  P. Cohen,et al.  Widespread Expression of Serum Amyloid A in Histologically Normal Human Tissues: Predominant Localization to the Epithelium , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[44]  T. van der Poll,et al.  Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees , 1994, The Journal of experimental medicine.

[45]  Thomas M Braun,et al.  Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. , 2011, Blood.

[46]  A. Ganser,et al.  Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[47]  I. Yakoub-Agha,et al.  Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD , 2011, Bone Marrow Transplantation.

[48]  E. De Pauw,et al.  Tritrophic interactions among Macrosiphum euphorbiae aphids, their host plants and endosymbionts: investigation by a proteomic approach. , 2010, Journal of insect physiology.

[49]  Virginia Espina,et al.  Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. , 2006, Experimental hematology.

[50]  T. van der Poll,et al.  Interleukin-6 Stimulates Coagulation, not Fibrinolysis, in Humans , 1996, Thrombosis and Haemostasis.

[51]  R. Soiffer,et al.  Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. , 2007, Blood.

[52]  Herbert Y. Lin,et al.  Hepcidin Regulation by BMP Signaling in Macrophages Is Lipopolysaccharide Dependent , 2012, PloS one.

[53]  Chi-kong Li,et al.  Elevated Serum Interleukin-15 Level in Acute Graft-Versus-Host Disease After Hematopoietic Cell Transplantation , 2003, Journal of pediatric hematology/oncology.

[54]  Thomas M Braun,et al.  Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin , 2008, Science Translational Medicine.

[55]  A. Barrett,et al.  Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. , 2007, Experimental hematology.

[56]  Bruce R. Blazar,et al.  Advances in graft-versus-host disease biology and therapy , 2012, Nature Reviews Immunology.

[57]  A. Ganser,et al.  Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2007, Blood.

[58]  J. Ferrara,et al.  Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.

[59]  D. Davalos,et al.  Fibrinogen as a key regulator of inflammation in disease , 2011, Seminars in Immunopathology.

[60]  David O. Nelson,et al.  Statistical challenges in the analysis of two-dimensional difference gel electrophoresis experiments using DeCyderTM , 2005, Bioinform..

[61]  J. Bolaños-Meade,et al.  Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. , 2012, Blood.

[62]  H. Einsele,et al.  Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. , 2011, Blood.

[63]  J. Dayer,et al.  High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation? , 2002, Autoimmunity reviews.

[64]  J. Foidart,et al.  Potential therapeutic target discovery by 2D-DIGE proteomic analysis in mouse models of asthma. , 2011, Journal of proteome research.